Gastrointestinal stromal tumours - sunitinib: review decision - January 2012
Review of NICE Technology Appraisal Guidance no. 179; Sunitinib for the treatment of gastrointestinal stromal tumours
The Institute proposed that the guidance should be transferred to the 'static guidance list' for Technology Appraisals.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal and TA179 will now be added to the static list.
This page was last updated: 27 January 2012